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Abstract Immunomodulation of the autoreactive T cell re-
sponse is considered a major strategy to control beta-cell au-
toimmunity, both in the natural history of type 1 diabetes and
in islet transplantation, which can be affected by autoimmuni-
ty recurrence. So far, these strategies have had modest results,
prompting efforts to define novel cellular and molecular tar-
gets to control autoreactive T cell expansion and activation.
Novel findings highlighted the important role of the homeo-
static cytokine interleukin-7 in inducing proliferation and dif-
ferentiation of autoreactive T cell clones that causes beta-cell
autoimmunity. In this review, we discuss recent evidences and
novel findings on the role of IL-7 mediated homeostatic T cell
proliferation in the process of beta-cell destruction and evi-
dences of how targeting IL-7 and its receptor could be an
innovative and effective strategy to control beta-cell
autoimmunity.
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Introduction
Type 1 diabetes is caused by the selective destruction of
pancreatic insulin-producing beta-cells by an immune-
mediated reaction, predominantly mediated by autoreactive
T cells [1]. CD4+ and CD8+ T cells able to recognize MHC
class II and class I restricted epitopes of the beta-cell-
associated antigens glutamic acid decarboxilase 65
(GAD65), proinsulin, islet tyrosine phosphatase (IA-2),
and zinc transporter 8 [2] have been found in patients with
type 1 diabetes using proliferation assays, ELISPOT, and
fluorescent class I and class II MHC multimers [3]. These
studies have also highlighted several key observations
concerning the nature of the T cell response toward beta-
cells. First, while naive T cells specific for beta-cell anti-
gens are commonly found in subjects with no signs of beta-
cell autoimmunity [4•], in patients with type 1 diabetes
autoreactive T cells show signs of previous antigen encoun-
ter, such as telomere shortening [5•], activation in the ab-
sence of co-stimulatory signals [6], and the expression of
the memory marker CD45RO [5•]. Second, an autoreactive
memory T cell response is difficult to control with standard
immunosuppression and is highly refractory to immuno-
modulatory molecules. This is testified by the limited effi-
cacy of recent clinical trials aiming to prevent or delay
immune-mediated beta-cell loss using GAD65 vaccination
[7], CTLA4-Ig [8], and humanized anti-CD3 antibody [9].
More aggressive approaches based on profound T cell de-
pletion, although effective early after treatment [10], were
later affected by frequent relapse of the autoimmune re-
sponse [11, 12]. Third, generation and expansion of
autoreactive T cell clones can occur under the influence
of homeostatic proliferation mediated by interleukin-7
(IL-7) [13]. The canonical antigen-specific proliferation
pathway relies on the autocrine production of IL-2 and
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the upregulation of the IL-2 receptor alpha (also known as
CD25). Therefore an important class of immunomodulato-
ry molecules was developed to target this pathway includ-
ing calcineurin inhibitors and anti-CD25 antibodies.
Recent evidences however clearly showed that T cells can
proliferate and acquire a memory phenotype upon activa-
tion of the IL-7/IL-7R axis [14••]. Moreover, recent find-
ings suggest that IL-7 is involved in the generation of T
cells with a stem cell-like memory phenotype (memory
stem T cells, Tscm) [15••] and in the reprogramming of T
cell bio-energetic metabolism for T cell proliferation [16].
While the interest on the homeostatic T cell proliferation
pathway is increasing in autoimmunity, there is a substan-
tial lack of molecules targeting this pathway in humans and
trials to assess whether this could be an effective approach
to control T cell-mediated beta-cell autoimmunity. In this
article, we discuss how the IL-7/IL-7R pathway can con-
tribute to the development of type 1 diabetes and how pre-
clinical models have demonstrated the efficacy of a selec-
tive targeting of this pathway. Finally, we discuss how, and
in which clinical setting, the targeting of the IL-7/IL-7R
pathway can be a therapeutic option for the prevention
and treatment of beta-cell autoimmunity.
IL-7 Production and Regulation
IL-7 is secreted by stromal cells located in the bone mar-
row, in peripheral lymphoid organs, and in the gastro-
intestinal tract [17]. These cells have yet to be fully char-
acterized; however, it appears that IL-7 transcripts are pro-
duced at a constitutive level and are not influenced by
extrinsic stimuli such as the concentration of IL-7 in a
negative feedback or the size of the T cell compartment.
Peripheral IL-7 concentration relies on consumption by IL-
7 receptor positive T cells. IL-7 production at a fixed rate
and consumption keeps the serum concentration of IL-7
below 5 pg/ml in physiological conditions. [18] This rep-
resents a limiting factor for T cell expansion. In an immune
system with a full T cell compartment, the concentration of
IL-7 is sufficient for the survival of a finite number of T
cells. IL-7 also maintains a slow rate of T cell proliferation
to counterbalance physiological T cell death. When the
peripheral T cell number is reduced (lymphopenia), the
serum concentration of IL-7 rises to supraphysiological
levels (Fig. 1). Remaining T cells in a lymphopenic envi-
ronment and in an IL-7 rich milieu enter the cell cycle, and
homeostatic T cell proliferation induced by IL-7 occurs.
The process is self-limiting as restoring the number of
peripheral T cells corresponds to an increased consumption
of IL-7. Homeostatic T cell proliferation stops when the
physiological T cell number and IL-7 concentration are
fully restored.
The IL-7/IL-7 Receptor Signaling Pathway
The high affinity IL-7 receptor results from the IL-7-mediated
crosslinking of the extracellular domains of the IL-7 receptor
alpha-chain (IL-7Rα; also known as CD127) and the common
cytokine receptor-γ chain (γc, also known as CD132).
Tyrosine kinases Janus kinases (JAK1) and JAK3 which are
linked to the intracellular domain of the γc mutually phos-
phorylate and their increased kinase activity, thus inducing
phosphorylation of the IL-7Rα intracellular domain and
allowing the binding of the signal inducer transducer and ac-
tivator of transcription factor 5 (STAT-5) which dimerizes and
translocates to the nucleus activating gene transcription [19].
Once in the nucleus, STAT5 regulates the expression of many
targets genes involved in T cell proliferation and survival,
including the upregulation of prosurvival Bcl-2 family mem-
bers, such as the main targets BCL-2, MCL-1, and BC-XL
[20] and downregulation of proapoptotic members of the
BCL-2 family, such as BAX or BIM [21]. Other STAT5-
regulated genes are Runt-related transcription factor 3
(Runx3), essential for T cell development and differentiation,
and the suppressor of cytokines signaling (SOCS), necessary
for negative feedback regulation of the cytokine signaling and
T cell compartment homeostasis.
In addition to survival, the IL-7R signaling induces T cell
proliferation through the repression of the cell cycle inhibitor
p27kip1 [22] and preventing degradation of Cdc25A [23]. T
cell proliferation is an energy-demanding process and neces-
sitates the incorporation of nutrient to increase the biomass
needed to produce daughter cells [24]. In order to meet the
bio-energetic demands for proliferation, T cells activate aero-
bic glycolysis. Despite a lower efficiency in ATP production
as compared to oxidative phosphorylation, glycolysis is an
anabolic process and provides also fundamental nutrients for
the synthesis of biological macromolecules [25]. The IL-7
signaling activates the PI3K/Akt pathway, which is funda-
mental for T cell proliferation. To sustain the bio-energetic
and metabolic needs, IL-7R signaling is also involved in the
activation of the glycolytic machinery, including the Akt-
mediated upregulation of the glucose transporter 1 (GLUT1)
[26] on the cell surface and the upregulation of the glycolytic
enzymes hexokinase II (HXKII) [16]. Excision of IL-7R on
mature Tcells in vivo results in size and growth reduction of T
cell compartment due to homeostatic mechanism impairment
and metabolic cellular machinery liability [27].
IL-7 in Beta-Cell Autoimmunity
In order to protect an individual from a wide range of different
pathogens, the T cell compartment needs to guarantee a broad
diversity of antigen specificity and a sufficient cell number to
mount an effective immune response [28]. The T cell
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repertoire can also include T cell clones reactive to self-anti-
gens, which escaped the negative selection process in the thy-
mus and circulate as naive T cells. These potentially patho-
genic clones are prevented from activation and proliferation
mainly by their low affinity for the cognate MHC-peptide
antigen complex which can deliver only weak signals as com-
pared to high affinity T cell receptors [29•]. The TCR signal
strength determines the T cell capacity to produce IL-2 and to
upregulate the IL-2Rα (also known as CD25) for an effective
expansion and differentiation in a T cell compartment with a
self-limiting size [30].
This competitive advantage of T cells with a high affinity
TCR is lost in an IL-7 rich milieu. While the IL-2Rα has an
inducible expression regulated by Tcell activation through the
TCR, the IL-7Rα is constitutively expressed by all T cells and
can induce Tcell proliferation when the circulating concentra-
tions of IL-7 reach supra-physiological levels [28]. Moreover,
the low affinity TCR-MHC self-peptide interactions, which
are required for T cell persistence, can give a selective advan-
tage to autoreactive T cell clones [29•]. Perturbations of the
IL-7/IL-7R axis can be associated with the activation of
autoreactive T cells.
In animal models, the non-obese diabetic (NOD) mouse
was shown to be affected by a chronic state of lymphopenia,
which is permissive for autoreactive homeostatic Tcell expan-
sion under the influence of IL-21 [31]. Increasing the number
of circulating Tcells by injection of complete Freund adjuvant
(CFA) at 3 weeks of age efficiently reduced the incidence of
diabetes. Direct evidences of the role of IL-7 in the autoim-
mune beta-cell destruction process come from the rat insulin
promoter (RIP)-lymphocytic choriomeningitis virus glycopro-
tein (GP)-transgenic mouse model [32•]. In this model, adop-
tive transfer of Smarta T cells restricted for the I-Ab-restricted
LCMV GP61-80 (p13) epitope together with polyclonal CD8
Tcells did not modify the incidence of diabetes. An increase in
the incidence of diabetes was reported only when lymphope-
nia was induced with cyclophosphamide or by exogenous
administration of IL-7. The diabetogenic effect of cyclophos-
phamide or IL-7 injection can be neutralized by blocking the
IL-7R with a monoclonal antibody.
Lymphopenia, which is associated with increased circulat-
ing levels of IL-7 represents a typical condition in which
autoreactive T cells can expand [28]. A relatively high risk
of autoimmunity development has been observed in patients
undergoing bone marrow transplantation after conditioning
regimen and profound T cell depletion. Immunosuppression
in patients receiving islet allotransplantation was associated
with IL-7-mediated expansion of autoreactive T cell clones
specific for GAD65 [14••]. Patients at risk for or with diag-
nosed type 1 diabetes have normal circulating levels of IL-7.
However, single nucleotide polymorphisms (SNPs) of the IL-
7Rαwere associatedwith an increased risk of developing type
1 diabetes and multiple sclerosis [33]. As for many other cy-
tokine receptors, a soluble form of the IL-7Rα has been iden-
tified and characterized for its capacity to bind to and inhibit
the interaction of IL-7 with the surface receptor in T cells. In
conditions of high blood glucose levels, the soluble IL-7Rα
undergoes a non-enzymatic glycation process, losing its buff-
ering capacity of IL-7 biological activity [34]. High levels of
circulating IL-7 can be found in neonates and persist for the
first 6 months of life [35]. Both GAD65 and proinsulin-
specific T cells with a naive phenotype are already present at
birth, and IL-7 was shown to promote in vitro proliferation
and activation of GAD65 and proinsulin-specific T cells ob-
tained from cord blood samples.
An IL-7 rich milieu can affect immune tolerance to self-
antigens by acting directly on the CD4+CD25+ regulatory T
cells (Treg) [36•]. The Treg network is essential to limit pro-
liferation of autoreactive T cell clones. Despite a low expres-
sion of the IL-7Rα, which makes Treg unresponsive to
Fig. 1 IL-7-mediated
homeostatic T cell proliferation.
In normal conditions, stromal
cells constitutively produce IL-7
which is consumed by T cells and
kept at low levels in the periphery.
After T cell depletion, IL-7 con-
centration becomes elevated and
remaining T cell start to prolifer-
ate in the IL-7 rich milieu. During
expansion, autoreactive T cell
clones can undergo expansion
and are included in a higher
number in the reconstituted T cell
pool
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physiological concentrations of circulating IL-7, STAT5 phos-
phorylation can be detected at pathological circulating con-
centrations of IL-7. The Treg response to IL-7 appeared to
correlate with the phenotype. While CD45RO+ memory
Treg remain anergic, CD45RO naive Treg strongly proliferate
in response to IL-7, thus acquiring a CD45RO+ memory phe-
notype. Importantly, once exposed to IL-7, both memory and
naive Treg have a reduced capacity to inhibit proliferation of
conventional T cells in response to autoantigens. The suppres-
sive capacity is fully restored upon IL-7 withdrawal. This
effect can be of importance in the islet transplantation setting
in which prolonged exposure of Treg to high circulating con-
centrations of IL-7 can impair the Treg capacity to control the
expansion of autoreactive and alloreactive T cells.
IL-7 and the Generation of Memory Stem T Cells
The memory T cell compartment is composed by several sub-
sets in different stages of differentiation [30]. Conventionally,
memory T cell populations can be divided according to the
differential expression of CD45RA, CCR7, and CD62L into
central memory (Tcm), effector-memory (Tem), and terminal-
ly differentiated effector-memory RA (Temra) [37]. All mem-
ory subsets are generated from a common naive T cell (Tn)
precursor according to a progressive differentiation model
[38]. In this model, Tn progress along a differentiation path-
way in the order of Tn, Tcm, Tem, and Temra. The final step of
differentiation generates terminally differentiated effector T
cells that are short lived and undergo to massive apoptosis
(contraction) when the immune response exhausts. It was un-
clear whether long-term T cell memory is maintained by the
conventional memory T cell subsets or by a long-lived T cell
precursor with self-renewal potential. In humans, convention-
al memory T cell subsets have indeed a rapid turnover and a
half-life of few weeks [39, 40]. The existence of a memory
precursor with stem cell-like properties was first hypothesized
and subsequently described in mice [41••], in humans [42••],
and in non-human primates [42••]. Tscm show a CD45RA+
CCR7+ naive phenotype associated with the expression of the
memory markers IL-2Rbeta and CD95 [42••]. Generation of
Tscm from naive Tcells involves the homeostatic cytokine IL-
7. In the classical antigen-specific activation pathway, T cell
receptor engagement and IL-2 provides strong signals for T
cell differentiation toward short-lived effector cells. In con-
trast, the homeostatic cytokine IL-7 sustains T cell prolifera-
tion without the robust differentiating activity of IL-2. In vitro
priming of naive T cells in the presence of IL-7 results in the
generation of T cells with phenotypic, functional, and gene
expression attributes found in naturally arising Tscm cells
[15••].
This is relevant to beta-cell autoimmunity because T cell
memory to beta-cell antigens is established before the onset of
type 1 diabetes and is then maintained for decades after the
disease onset, as testified in patients with type 1 diabetes re-
ceiving islet or pancreas transplants, in which despite immu-
nosuppression, can be associated with reactivation of autoim-
munity [43, 44]. Given the role of the IL-7/IL-7R axis in Tcell
autoimmunity and the long lasting memory to beta-cell anti-
gens observed in patients with type 1 diabetes, we previously
hypothesized that a T cell precursor with stem cell-like prop-
erties could be generated by autoantigen stimulation in the
presence of IL-7 [45]. Even though the existence of memory
stem Tcells reactive to beta-cell antigens has to be proven, this
population would be an ideal target cell for an innovative
approach to beta-cell autoimmunity. Most strategies were de-
signed to target activation/proliferation of pathogenic effector
Tcells. However, the identification and targeting of Tcells that
preserve long-termmemory to beta-cell antigen would be able
to eradicate the pathogenic T cell progeny. This approach is
similar in principle to that hypothesized to treat cancer by
targeting cancer stem cells [46]. In this theory, a permanent
eradication of a tumor mass can be achieved by selective
targeting of rare and slowly proliferating cancer stem cell pre-
cursors. In contrast, standard radio-chemotherapy targeting
the vast majority of rapidly proliferating cancer cells but not
cancer stem cells results in a high rate of tumor relapse.
Targeting IL-7 Mediated Homeostatic T Cell
Proliferation in Preclinical Models
Molecules with the ability to directly or indirectly target the
IL-7/IL-7R axis have been discovered and first tested in pre-
clinical models (Table 1). The IL-7/IL-7R axis has been im-
plicated in the development of autoimmune diabetes in the
NOD mouse model. Two reports showed how IL-7Rα block-
ade was effective to prevent and revert diabetes. In the first
report [47••], the selective inhibition of the IL-7Rα using a
monoclonal antibody was able to prevent diabetes after only
2–3 injections starting at week 9 of age. Disease remission
was complete and durable, after a 4-week cycle of anti-IL-
7Rα antibody starting at the time of diabetes onset. Anti-IL-
7R antibody was reported to act by inhibiting diabetogenic
effector-memory T cells (Tem). Diabetogenic Tem cells were
not depleted by IL-7Rα treatment but were instead
reprogrammed to suppress IFN-γ secretion and to upregulate
the inhibitory receptor programmed death 1 (PD-1). Tem cells
from anti-IL-7Rα-treated mice were also adoptively trans-
ferred in recipient mice without causing diabetes and demon-
strating that IL-7-signaling deprivation was related to a state
of cell intrinsic tolerance. In the second report [48••], treat-
ment with the IL-7Rα antibody resulted in the reduction of
IFN-γ-producing CD4+ (TH1) and IFN-γ-producing CD8+
(Tc1) T cells. As shown also in the first report, IL-7Rα anti-
body treatment induced upregulation of PD-1 expression in
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effector T cells that appeared to be necessary for maintenance
of tolerance, which could be reversed by PD-1 blockade.
Interestingly, in both models, IL-7Rα antibody treatment
was associated with an increased frequency of regulatory T
cells. The same monoclonal antibody raised against the IL-
7Rα was also tested on BALB/c mice receiving C57BL/6
islets under the kidney capsule, as model of islet transplanta-
tion in streptozotocin-induced diabetes [49•]. When started
3 weeks before islet infusion, the anti-IL-7Rα treatment in-
duced indefinite pancreatic islet allograft survival. This is of
interest in the field of islet transplantation where a single treat-
ment with an anti-IL-7Rα can potentially control both the
autoimmune and the alloimmune response to islet allografts.
Biological and pharmacological regulators of the IL-7/IL-
7R axis with a potential translation into the clinic have been
identified. As for other cytokine receptors, a soluble form of
the IL-7Rα (sCD127) has been identified in humans [50].
sCD127 is generated both by alternative splicing or shedding
of the membrane bound IL-7Rα. The amount of circulating
sCD127 is regulated by single nucleotide polymorphism
(SNP) of the IL-7Rα gene [51]. A SNP found in exon 6
(rs6897932) determines the extent of exon splicing.
Transcripts that skip exon 6 (C allele of rs6897932) encode
sCD127 [52]. The polymorphism determines an increase of
circulating levels of sCD127 and has been associated with an
increased susceptibility to type 1 diabetes. sCD127 can bind to
and inhibit IL-7 and is the only known endogenous regulator
of the IL-7 biological activity [34]. sCD127 display a low
affinity (Kd=10–8 M) for IL-7 which is 3 logs lower than
the affinity of IL-7 for the membrane IL-7Rα-γc-chain [53].
Nevertheless, sCD127 concentration in serum (70–80 ng/mL)
is 4 logs higher than physiological IL-7 concentration IL-7
(5 pg/ml) and is therefore expected to significantly influence
the IL-7 bioactivity. The generation of a modified sCD127
with higher affinity for IL-7 could have therapeutic
applications.
An interesting biological compound, which acts as a potent
downregulator of IL-7Rα signaling is the 15 kDa Tat protein
produced by the HIV virus [54]. Tat is secreted by HIV infect-
ed cells detectable in the serum of HIV-infected patients or in
supernatants from in vitro cultures. Tat enters the cytoplasm of
CD8+ T cells and interacts with the cytoplasmic tail of the IL-
7Rα causing clustering and downregulation from the cell sur-
face. The internalized IL-7Rα is then directed to the protea-
some for degradation.
Pharmacological modulation of IL-7Rα signaling can be
achieved by targeting downstream signaling such as JAK1
and JAK3. Tofacitinib is a potent inhibitor of JAK1 and
JAK3 and currently approved for the treatment of rheumatoid
arthritis (RA), has demonstrated effectiveness in the treatment
of psoriasis in phase III clinical trials, and is currently tested as
immunomodulator for organ transplantation [55]. Tofacitinib
was shown to impair Th1 and Th17 effector function; howev-
er, its action is broad and includes all γc-chain cytokines.
Other JAK inhibitors under evaluation in clinical trials for
autoimmune diseases include the JAK1 and JAK2 inhibitor
Ruxolitinib, the JAK1 inhibitor GLPG-0634, and the JAK3
antagonist VX-509. Even though none of these compounds is
selective for the IL-7/IL-7Rα signaling pathway, they can be
used in combination with selective inhibitors of the IL-7Rα to
potentiate the effectiveness.
Targeting IL-7-Mediated Homeostatic T Cell
Proliferation in Type 1 Diabetes and Islet
Transplantation
A humanized IgG1 monoclonal antibody that binds to and
inhibit the IL-7Rα has been developed by GlaxoSmithKline
and tested as single ascending doses study phase I clinical trial
on healthy volunteers to determine the safety, tolerability,
pharmacokinetics, pharmacodynamics, and immunogenicity
(NCT02293161, ClinicalTrials.gov identifier). The primary
outcome measures were expected in September 2015 and
not yet released.
The anti-IL-7Rα monoclonal antibody PF-06342674
(RN168) developed from Pfizer has been tested in phase 1b
in patients with multiple sclerosis (NCT02045732
ClinicalTrials.gov identifier) with the primary outcome to
evaluate adverse side effects and pharmacokinetic–
Table 1 Molecules targeting the
IL-7/IL-7R axis Study phase Molecule IL-7/IL-7R specificity Setting Refs
Clinical Anti-IL-7Rα mAb Yes T1D, MS N/A
Mycophenolate mofetil No Islet tx in T1D [14••]
JAK inhibitors No RA [55]
Preclinical Anti-IL-7Rα mAb Yes Diabetes in NOD
Islet tx
[47••, 48••, 49•]
Bz-423 No GVHD [59•]
2-DG+ metformin No Lupus [60•]
Experimental sCD127 Yes Human [34]
Tat protein Yes Human [54]
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pharmacodynamic properties. The trial is reported to have
been terminated in April 2015 due to a corporate decision
not related to safety or tolerability issues. A second trial was
designed to test the same antibody in patients with type 1
diabetes and is estimated to conclude in March 2016.
While waiting for the results of these trials in terms of
safety and tolerability and for the design of phase II and phase
III trials to determine whether blockade of the IL-7Rα is ef-
fective in the treatment of type 1 diabetes, it is important to
highlight the interest and the effort to explore the IL-7/IL-7R
axis as a potential target pathway to control beta-cell
autoimmunity.
As we previously reported, islet transplantation in patients
with type 1 diabetes is associated with IL-7-mediated homeo-
static proliferation of memory autoreactive Tcells. This model
also provided important evidences of the effect of classical
immunosuppressive drugs on the IL-7/IL-7R axis. The
mTOR inhibitor rapamycin and the calcineurin inhibitor
FK506 were ineffective on IL-7-mediated homeostatic T cell
proliferation at therapeutic serum level concentrations [14••].
Interestingly, the anti-CD25 antibody daclizumab by blocking
the interaction of CD25 with the γc chain, promotes the asso-
ciation of the IL-7Rα/γc complex resulting in an increased
sensitivity of T cells to IL-7 [56]. On the other hand, myco-
phenolate mofetil (MMF) was shown to reduce by 90 % the
rate of homeostatic T cell proliferation at therapeutic serum
level concentrations [14••]. MMF is a purine synthesis inhib-
itor acting very downstream in the proliferation process. Even
though the mechanisms of action suggest that inhibition of T
cell proliferation is not specific it represents the best therapeu-
tic option to control homeostatic proliferation at least in the
transplantation setting.
Future Perspectives
Recent findings suggest that the immune response can be ma-
nipulated by targeting the bio-energetic metabolism of T cells.
Both naive and memory T cell subsets are quiescent cells and
rely on oxidative phosphorylation to sustain housekeeping
functions [57]. However, proliferating cells like activated
and effector T cells upregulate oxidative phosphorylation to
meet the increased energetic demand and activates aerobic
glycolysis, which is better suited for the biosynthesis of cell
components, proliferation, and effector functions [58]. Bz-423
is a novel small molecule that inhibits the mitochondrial
F1F0-ATPase resulting in the increase of superoxide and in-
ducing selective apoptosis of alloreactive Tcells while sparing
proliferating hematopoietic stem cells using preferentially gly-
colysis [59•]. This strategy was successful in preventing graft
vs host disease while preserving immune system repopulation
in a mouse model. In a mouse model of systemic lupus ery-
thematosus (SLE), a combination treatment with the
glycolysis inhibitor 2-deoxy-D-glucose and the fatty acid ox-
idation inhibitor metformin was able to normalize bio-
energetic metabolism of T cells and reverse SLE [60•]. As
previously reported, there is a strong link between IL-7 sig-
naling and bio-energetic metabolism, especially the IL-7 de-
pendent activation of the glycolysis machinery. The Tcell bio-
energetic metabolism is a novel and quickly developing fron-
tier for developing innovative approaches to control IL-7-
mediated homeostatic T cell proliferation and beta-cell
autoimmunity.
Conclusions
IL-7-mediated homeostatic proliferation T cell clones have
gained increasing interest in the pathogenesis of type 1 diabe-
tes and in autoimmunity recurrence post pancreas or islet
transplantation. This prompted efforts into a better under-
standing of the molecules and pathways involved in the IL-
7/IL-7R axis signaling that can be selectively targeted to con-
trol homeostatic proliferation. Some of these are in first phase
clinical trials, and we need to consider other ways in which
homeostatic proliferation can be controlled and incorporate
such strategies in the therapy of beta-cell autoimmunity.
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